Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

What Changed In Bristol Myers Squibb's Story?

Drug approval Regulatory submission AI-generated analysis

πŸ“ˆ Bristol Myers Squibb is pivoting its strategic focus toward CELMoDs and radiopharmaceuticals, investing over $170 million in a new Indiana manufacturing facility for the latter.

πŸ’Š Opdivo remains the company's largest revenue driver with $9.3 billion in fiscal 2024 sales, though Q3 2026 revenue dipped 6% to $2.4 billion due to conversion to Opdivo Qvantig.

πŸ“‰ Legacy cancer therapies Revlimid and Pomalyst are facing steep declines, with Revlimid sales falling 48.9% in fiscal 2025 to $2.95 billion.

πŸ”¬ The first CELMoD drug, Zenbexus (iberdomide), received accelerated FDA approval, while the second candidate, mezigdomide, is awaiting an FDA decision scheduled for May 13, 2027.

🎯 Management aims to make CELMoDs foundational in multiple myeloma treatment to replace older therapies like Revlimid and Pomalyst over time.

πŸ“Š Opdivo Qvantig generated $334 million in the third quarter of fiscal 2026, with management projecting annualized sales exceeding $1.3 billion.

⚠️ Investors are advised to monitor combined Opdivo and Qvantig sales closely as the primary metric for BMY's performance ahead of the fiscal Q4 2026 earnings report in February 2027.

Bullish Signals
  • Bristol Myers Squibb is investing over $170 million into a new radiopharmaceutical manufacturing facility in Indiana, signaling strong commitment to its emerging platform.
  • The company's first CELMoD drug, Zenbexus (iberdomide), has secured accelerated FDA approval, validating the efficacy of its targeted protein degradation technology.
  • Opdivo Qvantig is successfully transitioning from the legacy drug, generating $334 million in Q3 2026 with management projecting annualized sales over $1.3 billion.
Risk Factors
  • Legacy cancer therapies Revlimid and Pomalyst are shrinking rapidly, with Revlimid sales plummeting 48.9% in fiscal 2025, creating immediate pressure on top-line growth.
Full Analysis
Bristol Myers Squibb (BMY) is shifting its strategic narrative from a primary focus on immuno-oncology to emphasizing newer drug platforms, specifically CELMoDs and radiopharmaceuticals. Management highlighted these platforms during its fiscal Q3 2026 earnings call in October 2026, citing strengthened conviction in targeted protein degradation technologies. The company is investing over $170 million into a new manufacturing facility in Indiana to support its radiopharmaceutical initiatives. The article details the performance of BMY's key assets, noting that Opdivo remains the largest cancer drug with fiscal 2024 revenue of $9.3 billion, though it faced a 6% quarterly decline in Q3 2026 due to conversion to the newer Opdivo Qvantig formulation. Conversely, older therapies Revlimid and Pomalyst are experiencing significant sales declines, falling 48.9% and 22.9% respectively in fiscal 2025, creating a strategic need for new revenue drivers. Management's strategy involves using CELMoDs to replace declining older drugs in the multiple myeloma market, with Zenbexus already approved and mezigdomide awaiting an FDA decision in May 2027. Analysts view this pivot as reassuring because it targets shrinking legacy sales, though risks remain regarding the timing of new drug approvals and the continued revenue transition from Opdivo to Qvantig ahead of the fiscal Q4 2026 report expected in February 2027.